Riskpilot← Back to searchSign inGet full accessApolans AB
ABActiveOrg 5592420813Kvarngatan 23 Lgh 1104Retail sale of pharmaceutical products · NACE 4773Est. 20200 employees
Revenue 2025
SEK 827K
+82692300% vs 2024
EBITDA margin
96.4%
+3649% vs 2024
Equity ratio
65.9%
Financial strength
Net profit 2025
SEK 472K
+432633% vs 2024
| Revenue | SEK 827K | +82692300% |
| EBITDA | SEK 797K | +3649% |
| Net profit | SEK 472K | +432633% |
| Total assets | SEK 1,3M | +434% |
| Equity | SEK 847K | +578% |
| Employees | 0 | — |
Legal name
Apolans AB
Org number
5592420813
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
12 februari 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska driva apoteksverksamhet, import och export av läkemedel samt därmed förenlig verksamhet. Kommer att hyra ut sig själv som apotekare, farmaceut, receptarie, konsult inom provisionshandel till företag med apoteksartiklar och till detaljhandel på internet med apoteksartiklar. Företaget ska investera i fastigheter och aktier också.
Address
Kvarngatan 23 Lgh 1104
Email
humanyun_pu@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 275 | 320 | 0 | 827 |
| Staff expenses | — | — | — | — | −1 | −0 |
| EBITDA | −4 | −5 | 244 | 266 | −22 | 797 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — | — |
| EBIT | −4 | −5 | 244 | 266 | −22 | 797 |
| Net financials | — | — | −1 800 | — | −1 | −10 |
| Profit before tax | −4 | −5 | −697 | 126 | 1 | 597 |
| Tax | −0 | −0 | −42 | −27 | −1 | −126 |
| Net profit | −4 | −5 | −739 | 99 | 0 | 472 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 25 | 25 | 143 | 277 | 241 | 1 285 |
| Equity | 21 | 16 | 26 | 125 | 125 | 847 |
| Long-term debt | 1 | 6 | 0 | 0 | — | — |
| Short-term debt | 4 | 4 | 77 | 72 | 36 | 168 |
| Total debt | 5 | 10 | 77 | 72 | 36 | 168 |
EBITDA margin
96.4%
This company
15.8%
Market median
+510% vs market
20202025
Equity ratio
65.9%
This company
38.2%
Market median
+73% vs market
20202025
Return on equity
55.7%
This company
18.4%
Market median
+203% vs market
20202025
Net profit margin
57.0%
This company
8.1%
Market median
+604% vs market
20202025
Asset turnover
0.64×
This company
1.12×
Market median
-43% vs market
20202025
Debt / equity
0.52×
This company
0.62×
Market median
+16% vs market
20202025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-02-01 – 2020-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apolans AB 
ApoXcel ABBoard members of Apolans AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Humayun Iqbal | Board of Directors | 0 companies |
| Nyla Humayun | Deputy Board Member | 0 companies |